ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $934,000.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 100,000 shares of the stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $9.34, for a total value of $934,000.00. Following the transaction, the insider now owns 1,596,494 shares of the company’s stock, valued at $14,911,253.96. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Sarina Tanimoto also recently made the following trade(s):

• On Tuesday, April 16th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.28, for a total transaction of $928,000.00.
• On Friday, March 22nd, Sarina Tanimoto sold 2,343 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.02, for a total value of $21,133.86.
• On Thursday, March 14th, Sarina Tanimoto sold 444 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.00, for a total value of $3,996.00.
• On Wednesday, February 28th, Sarina Tanimoto sold 98,778 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.02, for a total transaction of $890,977.56.
• On Monday, February 26th, Sarina Tanimoto sold 700 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.01, for a total transaction of $6,307.00.

ARS Pharmaceuticals Stock Down 2.9 %

NASDAQ:SPRY traded down $0.26 during mid-day trading on Thursday, reaching $8.80. 332,056 shares of the stock were exchanged, compared to its average volume of 596,857. ARS Pharmaceuticals, Inc. has a 1 year low of $2.55 and a 1 year high of $11.27. The company has a 50 day simple moving average of $9.05 and a 200-day simple moving average of $6.76. The stock has a market capitalization of $852.67 million, a P/E ratio of -15.44 and a beta of 0.88.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its earnings results on Thursday, March 21st. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. As a group, research analysts predict that ARS Pharmaceuticals, Inc. will post -0.69 EPS for the current year.

Analysts Set New Price Targets

SPRY has been the topic of several recent analyst reports. SVB Leerink raised ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the company from $6.00 to $18.00 in a report on Tuesday, March 5th. Leerink Partnrs upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 5th. Wedbush restated an “outperform” rating and issued a $19.00 target price on shares of ARS Pharmaceuticals in a report on Monday, March 11th. Finally, William Blair upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 20th.

Institutional Investors Weigh In On ARS Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. raised its stake in ARS Pharmaceuticals by 214.3% during the 3rd quarter. RA Capital Management L.P. now owns 9,459,678 shares of the company’s stock valued at $35,758,000 after acquiring an additional 6,450,000 shares during the last quarter. ClariVest Asset Management LLC purchased a new stake in shares of ARS Pharmaceuticals during the first quarter worth approximately $2,790,000. Franklin Resources Inc. lifted its holdings in shares of ARS Pharmaceuticals by 5.9% during the fourth quarter. Franklin Resources Inc. now owns 4,098,497 shares of the company’s stock worth $22,460,000 after purchasing an additional 229,988 shares during the period. Denali Advisors LLC acquired a new position in ARS Pharmaceuticals in the 4th quarter valued at $480,000. Finally, Capstone Investment Advisors LLC acquired a new position in ARS Pharmaceuticals in the 1st quarter valued at $739,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.